All In Biotech

Drug Trial Radar · NCT07362459

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

A Phase III, Randomized, Double-blind, Multicenter Clinical Study to Evaluate the Efficacy and Safety of SCTB14 Versus Pembrolizumab as First-Line Therapy in Patients With Driver Gene-Negative, TPS ≥10% Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 246 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

246

Planned (sponsor's estimate)

Start

Dec 30, 2025

Primary completion

Jul 2027

Study completion Sep 2029

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase III, randomized, double-blind study compares the efficacy and safety of SCTB14 versus pembrolizumab as first-line treatment in patients with driver gene-negative, TPS ≥10% locally advanced or metastatic non-small cell lung cancer (NSCLC). The primary objective is to assess superiority of SCTB14 over pembrolizumab in prolonging progression-free survival. Safety will be closely monitored.

Conditions

  • Non-Small Cell Lung Carcinoma (NSCLC)

Interventions

  • SCTB14Drug

    SCTB14 is administered at selected dose by intravenous infusion on Day 1 of each 3-week cycle.

  • PembrolizumabDrug

    Pembrolizumab is administered at a fixed dose of 200 mg by intravenous infusion on Day 1 of each 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Assessed by Blinded Independent Central ReviewTime frame: Up to approximately 1.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.